Clinical trials: Immunoglobulin
Advanced Malignant Solid Neoplasm, Extracranial Solid Neoplasm
SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies
This phase I trial studies the side effects of intratumoral injection of SD-101 and BMS-986178 in treating patients with solid malignancies that have spread to other places in the body.
- Conditions
- Advanced Malignant Solid Neoplasm, Extracranial Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03831295
- Testing
- Anti-OX40 Antibody BMS 986178, TLR9 Agonist SD-101
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Ronald Levy
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers
RATIONALE: Gathering information over time about patients' sense of being a burden on their caregiver, and caregivers' sense of burden on themselves, may help doctors learn more about the desire to die in patients with late-stage…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Depression, Leukemia
- Trial name
- NCT00770419
- Testing
- medical chart review, questionnaire administration, psychosocial assessment and care
- Sponsor
- Rutgers, The State University of New Jersey
End-Stage Kidney Disease (ESKD)
Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis
This study will evaluate three Investigational Medicinal Products (IMPs) called REGN9933, REGN7508, and REGN9533. The study is focused on participants with End-Stage Kidney Disease (ESKD) treated with hemodialysis and standard…
- Trial name
- NCT07759167
- Testing
- REGN9933, REGN7508, REGN9533
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- Regeneron Pharmaceuticals
Breast Cancer, Colon Cancer
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Background: The p53 gene normally helps to stop cancer cells from growing. However, when the p53 gene is mutated or damaged, cancer cells may grow unchecked.
- Conditions
- Breast Cancer, Colon Cancer, Pancreatic Cancer, Sarcoma
- Trial name
- NCT01386502
- Testing
- p53: 264-272 peptide, CT-011
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer
A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 as single agent in patients with HER2-positive /HER2-low locally advanced or metastatic gastric/ gastroesophageal…
- Trial name
- NCT05141747
- Testing
- MRG002
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Miracogen Inc.
Hematological Malignancy
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Primary Objective: Phase 1: To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984 (Isatuximab).
- Trial name
- NCT01084252
- Testing
- Isatuximab SAR650984, Dexamethasone
- Where
- 59 sites in United States, Argentina and 15 more
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Sanofi
Intrahepatic Cholangiocarcinoma
Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with anti-pd-1 antibody in patients with advanced hepatocellular carcinoma after progression on first line systemic therapy.
- Trial name
- NCT04299581
- Testing
- Camrelizumab, US/CT-guided Percutaneous Cryoablation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Breast Cancer Females
Optimal Application Timing of ADC Drugs for Advanced Breast Cancer
This study plans to initiate a prospective, randomized controlled trial to investigate the optimal timing of antibody drug conjugate (ADC) therapy in the management of advanced Human Epidermal Growth Factor Receptor 2…
- Trial name
- NCT07657130
- Testing
- Antibody drug conjugate, Chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Crohn Disease
Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas
To investigate the clinical efficacy of certolizumab pegol for fistula closure in Crohn's disease subjects with active draining fistulas.
- Trial name
- NCT00354367
- Testing
- Certolizumab pegol
- Sponsor
- UCB Pharma
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma
Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma
This research trial is studying how Ch14.18 acts in the body of younger patients with high-risk neuroblastoma. Studying samples of blood from patients with cancer receiving Ch14.18 may help doctors learn more about how this drug…
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neurotoxicity Syndrome, Pain
- Trial name
- NCT01418495
- Testing
- Cytology Specimen Collection Procedure, Pharmacological Study
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Adult's Still Disease
Efficacy and Safety of Tocilizumab in Adult's Still Disease
Patients with adult's Still disease suffer from acute inflammatory symptoms such as fever, arthritis, rash, and acute phase response often requiring high dose corticosteroids.
- Trial name
- NCT01002781
- Testing
- Tocilizumab
- Where
- 4 sites in Israel
- Volunteers
- 10 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Lymphoma
Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, and vincristine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00726700
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Volunteers
- 109 people
- Sponsor
- Universität des Saarlandes
Non-proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
- Trial name
- GLOW (NCT05066230)
- Testing
- KSI-301
- Where
- 61 sites in United States, Czechia and 5 more
- Volunteers
- 253 people
- Sponsor
- Kodiak Sciences Inc
Hepatocellular Carcinoma Non-resectable
PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC
The vast majority of primary liver cancer (90%) is hepatocellular carcinoma (HCC), and the majority of HCC patients have been locally advanced or metastatic disease when they are diagnosed in clinics.
- Trial name
- PLTHCC (NCT04273100)
- Testing
- PD-1 mAb combined with TACE and lenvatinib
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Healthy Male Volunteers
A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single ascending dose (SAD) administration of E6011 in Japanese healthy volunteers.
- Trial name
- NCT01731275
- Testing
- E6011
- Where
- Japan
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Eisai Co., Ltd.
Atopic Dermatitis, Psoriasis
Clinical, Psychological and Genetic Characteristics in Dermatological Patients
Atopic dermatitis (AD) and psoriasis (PS) are chronic, relapsing dermatological disorders with a high rate of psychiatric co-morbid pathology represented with depression.
- Trial name
- NCT03831646
- Where
- Kazakhstan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Astana Medical University
Brain and Central Nervous System Tumors, Metastatic Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. This may be effective treatment for primary or metastatic brain tumors.
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Neuroblastoma
- Trial name
- NCT00003461
- Testing
- surgical procedure, astatine At 211 monoclonal antibody 81C6
- Where
- United States
- Sponsor
- Duke University
Infusion Reaction, Monoclonal Antibody
Efficacy of Montelukast in Reducing the Incidence and Severity of Monoclonal Antibodies Associated Infusion Reactions
The use of monoclonal antibodies (MA) either alone or as part of chemoimmunotherapy in oncology, benign and malignant hematology is expanding.
- Trial name
- NCT04198623
- Testing
- Montelukast 10 Mg Oral Tablet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Sarcoma, Wilm's Tumor
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer
This study will examine the safety and efficacy of ipilimumab-an experimental cancer treatment drug used to boost immune response-in children, adolescents, and young adults.
- Conditions
- Sarcoma, Wilm's Tumor, Lymphoma, Neuroblastoma
- Trial name
- NCT01445379
- Testing
- Ipilimumab
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myelodysplastic Syndromes
Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia
RATIONALE: Monoclonal antibodies can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00618696
- Testing
- anti-CD45 monoclonal antibody AHN-12, yttrium Y 90 anti-CD45 monoclonal antibody AHN-12
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.